News

Application period for the Startup Rally competition initiated by the Ministry of Industry and Trade of Russia ends June 1, 2019. Primer Capital COO Elizaveta Rozhdestvenskaya, as one of the judges, will be evaluating the projects of teams working on the development of new drugs, diagnostic test systems and medical products.

Primer Capital, the leading Russian pharma and biotech venture fund, partnered with the acceleration program launched by AstraZeneca and Skolkovo Foundation.

New cell products and technologies breakthroughs for targeted cancer therapy can dramatically change therapy prognosis for thousands of patients.
On April 24, within the Skolkovo StartUp Tour 2019 in Novosibirsk, Primer Capital and the Novosibirsk innovation company ECAR signed an agreement with the intention to collaborate on the development of cellular therapy for the treatment of metastatic hormone-sensitive prostate cancer.

Hemofarm, a startup and the developer of a biotech drug for patients diagnosed with multiple myeloma and non-Hodgkin's lymphoma, has become a resident at the Bayer innovation research lab CoLabrator®.

The new compound, called ACT017, developed by Primer Capital portfolio project, French startup Acticor Biotech in a phase 1 study on healthy volunteers showed it could inhibit clot formation without prolonging bleeding time. It is a marker that indicates increased risk of hemorrhage, according to results published in Arteriosclerosis, Thrombosi and Vascular Biology, an American Heart Association journal.

Primer Capital, Tatchempharmpreparaty JSC and Kazan Federal University (KFU) are to launch a new innovative pharma project to cure epilepsy.
On April 11, during the Russian Venture Forum in Kazan, Primer Capital, Tatchempharmpreparaty JSC and KFU signed a term-sheet to join their efforts on developing an anti-epileptic drug.

On April 11th, 2019, one the largest investment conferences in Eurasia, the Russian Venture Forum took place in Kazan. Alongside the representatives of I2BF Global Ventures, Skolkovo, Tatneft, Sberbank, Larix, Starta Capital, Vnesheconombank, Primer Capital COO Elizaveta Rozhdestvenskaya took part in the panel discussion dedicated to the collective investment models.

Primer Capital team of experts was invited to judge the participants at the “Biotech in medicine and agriculture” contest within the Start Up Tour which started on February 5th in Kemerovo and will go on until April 24th.

“Expert” Group of Companies and Intellogic LLC (Botkin.AI platform is the portfolio project of Primer Capital and ExpoCapital) reached an agreement on strategic cooperation in the creation and implementation of products using artificial intelligence technologies in healthcare.

Primer Capital COO Elizaveta Rozhdestvenskaya interviewed by the M-Health Congress 2019 organizers.